Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study

Larochelle, Marc R., Bernson, Dana, Land, Thomas, Stopka, Thomas J., Wang, Na, Xuan, Ziming, Bagley, Sarah M., Liebschutz, Jane M., Walley, Alexander Y.·2018·Annals of Internal Medicine
DOI 10.7326/m17-3107

Cited by (1,000)

Items 501–600 of 1,000

  1. The Substance Use Treatment and Recovery Team (START) study: protocol for a multi-site randomized controlled trial evaluating an intervention to improve initiation of medication and linkage to post-discharge care for hospitalized patients with opioid use disorder
    Allison J. Ober, Cristina M. Murray-Krezan, Kimberly Ann Page, Peter D. Friedmann, Karen Chan Osilla, Stephen Ryzewicz, Sergio Huerta, Mia W. Mazer, Isabel M. Leamon, Gabrielle Messineo et al. · 2022 · Addiction Science & Clinical Practice
  2. Low dose IV buprenorphine inductions for patients with opioid use disorder and concurrent pain: a retrospective case series
    John P. Murray, Geoff Pucci, George W. Weyer, Mim Ari, Sarah Dickson, Angela Kerins · 2023 · Addiction Science & Clinical Practice
  3. 18-Month efficacy and safety analysis of monthly subcutaneous buprenorphine injection for opioid use disorder: Integrated analysis of phase 3 studies
    Daniel Rutrick, Susan M. Learned, Brent Boyett, David R. Hassman, Sunita Shinde, Yue Zhao · 2023 · Journal of Substance Use and Addiction Treatment
  4. Characteristics of post-overdose outreach programs and municipal-level opioid overdose in Massachusetts
    Simeon D. Kimmel, Ziming Xuan, Shapei Yan, Audrey M. Lambert, Scott W. Formica, Traci C. Green, Jennifer J. Carroll, Sarah Mary Bagley, David Rosenbloom, Leo A. Beletsky et al. · 2023 · International Journal of Drug Policy
  5. Positive contact and empathy as predictors of primary care providers’ willingness to prescribe medications for opioid use disorder
    Lindsay Y. Dhanani, William C. Miller, Orman Trent Hall, Daniel Brook, Janet E. Simon, Vivian Fei-ling Go, Berkeley A. Franz · 2023 · SSM - Mental Health
  6. Psilocybin for Opioid Use Disorder in Two Adults Stabilized on Buprenorphine: A Technical Report on Study Modifications and Preliminary Findings
    Christopher R. N. Nicholas, David M. Horton, Julia Malicki, Amelia Baltes, Paul R. Hutson, Randall Brown · 2023 · Psychedelic Medicine
  7. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective
    Sun Ah Choi, Connie H. Yan, Nicole Gastala, Daniel R. Touchette, Paul M. Stranges · 2023 · Journal of Substance Use and Addiction Treatment
  8. Digital health interventions to support women with opioid use disorder: A scoping review
    Melissa Ward‐Peterson, Constance Guille, Ayesha Jafry, Tendai Gwanzura, Kayla Pryce, Patrice Lewis, Kathleen T. Brady · 2024 · Drug and Alcohol Dependence
  9. Opioid Use Disorder Treatment Decision Making And Care Navigation Upon Release From Prison: A Feasibility Study
    Caleb J. Banta‐Green, Anthony S. Floyd, Kristin Vick, Jen Arthur, Theresa J. Hoeft, Judith I. Tsui · 2019 · Substance Abuse and Rehabilitation
  10. Prescribing Naloxone to High-Risk Patients in the Emergency Department: Is it Enough?
    Scott G. Weiner, Jason A. Hoppe · 2021 · The Joint Commission Journal on Quality and Patient Safety
  11. Effectiveness of a substance use treatment program for veterans with chronic pain and opioid use disorder
    Ralph C Ward, Yi‐lang Tang, Robert Neal Axon, Jennifer Casarella, Natasha Whitfield, Sheila A. M. Rauch · 2021 · Journal of Substance Abuse Treatment
  12. The Impact of Pediatric Opioid-Related Visits on U.S. Emergency Departments
    Tiffany Champagne‐Langabeer, Marylou Cárdenas-Turanzas, Irma T. Ugalde, Christine Bakos‐Block, Angela L. Stotts, Lisa Marie Cleveland, STEVEN J. SHOPTAW, James R. Langabeer · 2022 · Children
  13. Higher buprenorphine dose associated with increased treatment retention at low threshold buprenorphine clinic: A retrospective cohort study
    Lea Selitsky, Courtney D. Nordeck, Ashley Q. Truong, Deborah Agus, Megan E. Buresh · 2023 · Journal of Substance Use and Addiction Treatment
  14. Supporting Providers After Drug Overdose Death
    Amy M. Yule, FRANCES RUDNICK LEVIN · 2019 · American Journal of Psychiatry
  15. Effectiveness of micro-induction approaches to buprenorphine initiation: A systematic review protocol
    Jessica Moe, Mary M. Doyle‐Waters, Fiona O’Sullivan, Corinne Michèle Hohl, Pouya Azar · 2020 · Addictive Behaviors
  16. Retention Strategies for Medications for Addiction Treatment in Adults With Opioid Use Disorder: A Rapid Evidence Review
    Brian L. Chan, Emily G. Gean, Irina Arkhipova-Jenkins, J Gilbert, Jennifer Hilgart, Celia V. Fiordalisi, Kimberly Hubbard, Irene Brandt, Elizabeth Stoeger, Robin A. Paynter et al. · 2020
  17. Drug Treatment Perspectives and Experiences Among Family and Friends of People Who Use Illicit Opioids: A Mixed Methods Study
    Susannah Slocum, Catherine E. Paquette, Robin A. Pollini · 2022 · SSRN Electronic Journal
  18. Reducing perceived barriers to scaling up overdose education and naloxone distribution and medications for opioid use disorder in the United States in the HEALing (Helping End Addiction Long-Term®) communities study
    Hannah K. Knudsen, Daniel Morris Walker, Nicole A. Mack, Elizabeth N. Kinnard, Timothy R. Huerta, LaShawn Glasgow, Louisa Gilbert, Bryan R. Garner, Anindita Dasgupta, Redonna K. Chandler et al. · 2024 · Preventive Medicine
  19. Patient outcomes following buprenorphine treatment for opioid use disorder: A retrospective analysis of the influence of patient‐ and prescriber‐level characteristics in Massachusetts, USA
    Gary J. Young, Tianjie Zhu, Md Mahmudul Hasan, Farbod Alinezhad, Leonard D. Young, Md. Noor‐E‐Alam · 2024 · Addiction
  20. Private Equity Acquiring Large Shares Of The Opioid Treatment Market Without Changing Market-Level Methadone Supply
    Yashaswini Singh, Jonathan Cantor, Christopher Whaley, Bryant Shuey, Rebecca C. Bilden, J. Travis Donahoe · 2025 · Health Affairs
  21. Opioid agonist therapy for opioid use disorder in primary versus specialty care
    Danielle Perry, Jessica E. M. Kirkwood, Marissa Doroshuk, Michael D. Kelmer, Christina S. Korownyk, Joey Ton, Scott Garrison · 2025 · Cochrane Database of Systematic Reviews
  22. Buprenorphine/naloxone associated with a reduced odds of fentanyl exposure among a cohort of people who use drugs in Vancouver, Canada
    Samantha Young, Kanna Hayashi, Cameron J Grant, M‐J Milloy, Kora DeBeck, Evan Wood, Nadia S. Fairbairn · 2021 · Drug and Alcohol Dependence
  23. Barriers and attitudes reported by Canadian emergency physicians regarding the initiation of buprenorphine/naloxone in the emergency department for patients with opioid use disorder
    Tyson Savage, Marshall Ross · 2021 · Canadian Journal of Emergency Medicine
  24. State Policy and the Breadth of Buprenorphine-Prescriber Networks in Medicaid Managed Care
    Mark Katz Meiselbach, Coleman Drake, Jane M. Zhu, Brynna Manibusan, Dylan Nagy, Mark Sorbero, Brendan K. Saloner, Bradley D. Stein, Daniel E. Polsky · 2023 · Medical Care Research and Review
  25. Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: A cohort study
    Andrew D. Tipping, Molly Nowels, Clara Moore, Hillary Samples, Stephen Crystal, Mark Olfson, Arthur Robinson Williams, Jodi M. Heaps‐Woodruff · 2023 · Journal of Substance Use and Addiction Treatment
  26. Missed Opportunities for Treatment of Opioid Use Disorder in the Hospital Setting: Updating an Outdated Policy
    Justin Berk, Kendall M. Rogers, Deanna J Wilson, Ashish P. Thakrar, Leonard Samuel Feldman · 2019 · Journal of Hospital Medicine
  27. Treating Opioid Use Disorder and Related Infectious Diseases in the Criminal Justice System
    Daniel E. Winetsky, Aaron D. Fox, Ank E. Nijhawan, Josiah D. Rich · 2020 · Infectious Disease Clinics of North America
  28. Civil commitment for opioid misuse: do short-term benefits outweigh long-term harms?
    John C. Messinger, Daniel J. Ikeda, Ameet Sarpatwari · 2021 · Journal of Medical Ethics
  29. Buprenorphine utilization among all Washington State residents' based upon prescription monitoring program data - Characteristics associated with two measures of retention and patterns of care over time
    Caleb J. Banta‐Green, Ryan N. Hansen, Eric M. Ossiander, Cathy R. Wasserman, Joseph O. Merrill · 2021 · Journal of Substance Abuse Treatment
  30. Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders
    Mukaila A. Raji, Shivani Priyadarshni, Xiaoying Yu, Biai Dominique Elmir Digbeu, Yong‐Fang Kuo · 2022 · The American Journal of Medicine
  31. Changes in transmucosal buprenorphine utilization for opioid use disorder treatment during the COVID‐19 pandemic in Kentucky
    Feitong Lei, Michelle R. Lofwall, Patricia Rippetoe Freeman, Emily Slade, Rachel Vickers‐Smith, Svetla S. Slavova · 2022 · The Journal of Rural Health
  32. The Community-Based Medication-First program for opioid use disorder: a hybrid implementation study protocol of a rapid access to buprenorphine program in Washington State
    Caleb J. Banta‐Green, Mandy D. Owens, Jason R. Williams, Jeanne M. Sears, Anthony S. Floyd, Wendy Williams‐Gilbert, Susan Kingston · 2022 · Addiction Science & Clinical Practice
  33. In-Hospital Methadone Enrollment: a Novel Program to Facilitate Linkage from the Hospital to the Opioid Treatment Program for Vulnerable Patients with Opioid Use Disorder
    Susan L. Calcaterra, Scott Saunders, Eric Grimm, Emma Maki-Gianani, Angela Keniston, Angi Wold, Angela Bonaguidi · 2023 · Journal of General Internal Medicine
  34. Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
    Priya Jain, Kimberley McKinnell, Rose Marino, Prashanthi Vunnava, Marie A. Liles-Burden, Avani Desai, Madé Wenten, James L. Fratantonio, Sarah C. Akerman, Maria A. Sullivan et al. · 2020 · Drug Safety
  35. Quality of Buprenorphine Care for Insured Adults With Opioid Use Disorder
    Kelly E. Anderson, Brendan K. Saloner, Julia Eckstein, Christine E. Chaisson, Sarah Hudson Scholle, Lauren L. Niles, Sydney Morss Dy, G. Caleb Alexander · 2021 · Medical Care
  36. Expanding access to nurse-managed medication for opioid use disorder
    Travis Andrew Cos, Laura E. Starbird, Heeyoung Lee, Bianca Chun, Kristine Gonnella, Jillian Bird, Kae Rivers Livsey, Shelley Bastos, Marie Claire O’Brien, I. D. Clark et al. · 2021 · Nursing Outlook
  37. In our responses to the overdose epidemic, we cannot forget pregnant and postpartum people
    Brooke S. West, Sugy Choi, Mishka Terplan · 2023 · International Journal of Drug Policy
  38. Addiction consult service involvement in PrEP and PEP delivery for patients who inject drugs admitted to an urban essential hospital
    Hallie A. Rozansky, Paul J. Christine, Morgan Younkin, Jason M. Fox, Zoe Weinstein, Sebastián Suárez, Jessica Stewart, Natalija Mead Farrell, Jessica L. Taylor · 2024 · Addiction Science & Clinical Practice
  39. Transformation of the HIV treatment cascade for people who inject drugs in Ukraine
    Daniel J. Bromberg, Delaney Rhoades, Lynn M. Madden, Roman Ivasiy, Anna Meteliuk, Iryna Pykalo, Myroslava Filippovych, Benjamin M. Nikitin, Scott O. Farnum, Tetiana Fomenko et al. · 2024 · AIDS
  40. State drug caps associated with fewer Medicaid-covered prescriptions for opioid use disorder, 2017-2022
    Robert J. Besaw, Carrie E Fry · 2024 · Health Affairs Scholar
  41. Medications for Opioid Use Disorder: Patients’ Experience, Knowledge, and Preferences in the Era of Illicitly Manufactured Fentanyl
    Sarah K. Casey, Sydney McGovern, Susan Regan, Sarah E. Wakeman · 2025 · Substance Use & Addiction Journal
  42. Longitudinal effects of interoceptive awareness training as an adjunct to medication treatment for opioid use disorder: A randomized clinical trial of Mindful Awareness in Body-oriented Therapy
    Cynthia J Price, Kenneth C. Pike, Joseph O. Merrill · 2025 · Drug and Alcohol Dependence
  43. Barriers to Buprenorphine Initiation in Patients Using Fentanyl
    Sarah Sharfstein Kawasaki, Jane M. Liebschutz, Cristina M. Murray-Krezan, Galen E. Switzer, Samantha Nash, Kwonho Jeong, Erin L. Winstanley · 2026 · JAMA Network Open
  44. Quantifying Barriers to Medications for Opioid Use Disorder in Skilled Nursing Facilities in a Southwestern Metropolitan Area
    Bethany Gutfrucht, Eileen Barrett · 2021 · Journal of the American Medical Directors Association
  45. A randomized clinical trial of strengths-based case management to link emergency department patients to opioid use disorder treatment
    Michael P. Bogenschutz, Ryan P. McCormack, Richard Charles Rapp, Sarah E. Meyers-Ohki, Sarah E. Mennenga, Amber Regis, Rhonda Kolaric, Richard Glisker, Peter P. Greco · 2022 · Journal of Substance Abuse Treatment
  46. Fatalities Involving Substance Use Among US Oil and Gas Extraction Workers Identified Through an Industry Specific Surveillance System (2014–2019)
    Alejandra Ramirez‐Cardenas, Kaitlin C. Wingate, Richard J. Pompei, Bradley S. King, Kenneth A. Scott, Kyla Hagan‐Haynes, L. Casey Chosewood · 2023 · Journal of Occupational and Environmental Medicine
  47. Implementation strategies to address the determinants of adoption, implementation, and maintenance of a clinical decision support tool for emergency department buprenorphine initiation: a qualitative study
    Matthew Simpson, Carly Ritger, Jason A. Hoppe, Wesley C. Holland, Megan A. Morris, Bidisha Nath, Edward R. Melnick, Caroline K. Tietbohl · 2023 · Implementation Science Communications
  48. Perspectives on and experiences of emergency department–initiated buprenorphine among clinical pharmacists: A multi-site qualitative study
    Marissa Justen, Eva Jennifer Edelman, Marek Cezary Chawarski, Edouard Coupet, Ethan A. Cowan, Michael S. Lyons, Patricia H. Owens, Shara H. Martel, Lynne D. Richardson, Richard Eric Rothman et al. · 2023 · Journal of Substance Use and Addiction Treatment
  49. Impact of Medicaid Expansion on Inclusion of Medications for Opioid Use Disorder in Homeless Adults’ Treatment Plans
    Natalie Swartz, Sethu Odayappan, Avik Chatterjee, David Cutler · 2022 · Journal of Substance Use and Addiction Treatment
  50. Point/counterpoint: Should full agonist opioid medications be offered to hospitalized patients for management of opioid withdrawal?
    Sam J. Stern, Joseph L. D’Orazio, Brian D. Work, Susan L. Calcaterra, Ashish P. Thakrar · 2023 · Journal of Hospital Medicine
  51. Unmet need for medication for opioid use disorder among persons who inject drugs in 23 U.S. cities
    Senad Handanagić, Dita Broz, Teresa Finlayson, Dafna Kanny, Cyprian Wejnert · 2024 · Drug and Alcohol Dependence
  52. County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities
    John G. Rizk, Jannat Saini, Kyungha Kim, Uzma Pathan, Danya M. Qato · 2024 · PLoS ONE
  53. The cascade of care for commercially-insured persons with opioid use disorder and comorbid HIV and HCV infections
    Roman Ivasiy, Lynn M. Madden, Elizabeth E. DiDomizio, Kimberly Johnson, Eteri Machavariani, Bachar Ahmad, David Oliveros, Adith V Ram, Natalie Kil, Frederick Lewis Altice · 2024 · Drug and Alcohol Dependence
  54. Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails
    Sandra Ann Springer · 2024 · JAMA Network Open
  55. Strategies to improve implementation of medications for opioid use disorder reported by veterans involved in the legal system: A qualitative study
    Erica Ferro Morse, Ingrid A. Binswanger, Emmeline N. Taylor, Caroline P. Gray, Matthew A. Stimmel, Christine Timko, Alex H. S. Harris, David A. Smelson, Andrea K. Finlay · 2021 · Journal of Substance Abuse Treatment
  56. The Emergency Department Longitudinal Integrated Care (ED-LINC) intervention targeting opioid use disorder: A pilot randomized clinical trial
    Lauren Whiteside, Ly Huynh, Sophie C. Morse, Jane P Hall, William J. Meurer, Caleb J. Banta‐Green, Hannah Scheuer, Rebecca J. Cunningham, Mark P. McGovern, Douglas Zatzick · 2021 · Journal of Substance Abuse Treatment
  57. COVID-19 impact on opioid overdose after jail release in Massachusetts
    Peter D. Friedmann, Devon Dunn, Pryce S. Michener, Dana Bernson, Thomas J. Stopka, Ekaterina Pivovarova, Warren J. Ferguson, Rebecca E. Rottapel, Randall A. Hoskinson, Donna Wilson et al. · 2023 · Drug and Alcohol Dependence Reports
  58. Experiences with Medications for Addiction Treatment Among Emergency Department Patients with Opioid Use Disorder
    Charlotte E. Goldfine, Brittany P. Chapman, Melissa Taylor, Evan Stuart Bradley, Stephanie Carreiro, Rochelle K. Rosen, Kavita M. Babu, Jeffrey T. Lai · 2023 · Western Journal of Emergency Medicine
  59. “I’m Clean and Sober, But Not Necessarily Free”: Perceptions of Buprenorphine Among Patients in Long-Term Treatment
    Jessica J. B. Wyse, Travis I. Lovejoy, Adam J. Gordon, Katherine Mackey, Anders Herreid-O’Neill, Benjamin J. Morasco · 2023 · Substance Abuse
  60. Medications for addiction treatment initiated from the emergency department: Ethical considerations
    Kenneth D. Marshall, Arthur R. Derse, Kenneth Victor Iserson, Nicholas H. Kluesner, Laura E. Vearrier · 2019 · The American Journal of Emergency Medicine
  61. The Opioid Epidemic Blunted the Mortality Benefit of Medicaid Expansion
    Brandon W. Yan, Frank Allen Sloan, W. John Boscardin, Felicia B. Guo, R. Adams Dudley · 2020 · Medical Care Research and Review
  62. Four models of pharmacist‐integrated office‐based opioid treatment
    Olivia Caron, Allison E. Fay, Haley Pressley, Gwen Seamon, Shawn Riser Taylor, Courtenay Gilmore Wilson · 2022 · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY
  63. Closing the gaps in opioid use disorder research, policy and practice: conference proceedings
    Matthew Miclette, Jared A. Leff, Isabella Cuan, Jeffrey H. Samet, Brendan K. Saloner, Gary Mendell, Yuhua Bao, Michael A. Ashburn, Marcus A. Bachhuber, Bruce R. Schackman et al. · 2018 · Addiction Science & Clinical Practice
  64. Rates of substance use disorder treatment seeking visits after emergency department-initiated buprenorphine
    Lindsey K. Jennings, Carolyn Bogan, Jenna L. McCauley, Angela D. Moreland, Suzanne Lane, Ralph C Ward, Karen J. Hartwell, Louise F. Haynes, Kathleen T. Brady · 2020 · The American Journal of Emergency Medicine
  65. Optimizing Retention Strategies for Opioid Use Disorder Pharmacotherapy: The Retention Phase of the Ctn-0100 Trial (RDD)
    Matisyahu Shulman, Sarah E. Meyers-Ohki, Patricia Novo, Scott E. Provost, Kaitlyn Ohrtman, Paul C. Van Veldhuisen, Neal L. Oden, Michael Christopher Otterstatter, Genie L. Bailey, David Liu et al. · 2024 · Contemporary Clinical Trials
  66. Effectiveness of Mutual Help Groups for Illicit Drug Use Disorders: A Review of the Current Literature
    Wayne E. Kepner, Keith N. Humphreys · 2025 · Current Addiction Reports
  67. Availability of Medications for Opioid Use Disorder in Opioid Treatment Programs
    Zoe Lindenfeld, Jonathan Cantor, Amanda I. Mauri, Sachini N. Bandara, Aarya Suryavanshi, Noa Krawczyk · 2025 · JAMA Network Open
  68. Recommendations for Addressing In-Hospital Substance Use From a National Delphi Consensus Process
    Joseph H. Donroe, Susan L. Calcaterra, Caty Simon, Melissa B. Weimer, Zina Huxley‐Reicher, Lisa B. Puglisi, Kristine Torres‐Lockhart, Orman Trent Hall, James Bhandary-Alexander, John Encandela et al. · 2025 · JAMA Network Open
  69. Comparison of Extended-Release Buprenorphine Doses for Treating High-Risk Opioid Use
    Rajinder Shiwach, Bernard Le Foll, Hannu Alho, Kelly E. Dunn, Stephanie Strafford, Yue Zhao, Robert L. Dobbins · 2025 · JAMA Network Open
  70. Evaluating the optimal duration of medication treatment for opioid use disorder
    Corey J. Hayes, Rebecca A. Raciborski, Mahip Acharya, Nahiyan Bin Noor, Edward V. Nunes, Theresa M. Winhusen · 2026 · Addiction
  71. Loneliness and fearfulness are associated with non-fatal drug overdose among people who inject drugs
    Oluwaseun O Falade-Nwulia, Kathleen Ward, Karla D. Wagner, Hamidreza Karimi‐Sari, Jeffrey Hsu, Mark Sulkowski, Carl Asher Latkin, Evaristus A. Nwulia · 2024 · PLoS ONE
  72. Impact of the Communities That HEAL Intervention on Buprenorphine-Waivered Practitioners and Buprenorphine Prescribing
    Thomas J. Stopka, Denise C. Babineau, Erin Bray Gibson, Charles E. Knott, Debbie M. Cheng, Jennifer Villani, Jonathan M. Wai, Derek Blevins, James L. David, Dawn Goddard‐Eckrich et al. · 2024 · JAMA Network Open
  73. Association of buprenorphine retention and subsequent adverse outcomes following non-fatal overdose: An analysis using statewide linked Maryland databases
    Olivia K. Sugarman, Brendan K. Saloner, Thomas M. Richards, Elyse C. Lasser, Teresa Heath, Shima Idries, Jonathan P. Weiner, Sachini N. Bandara · 2024 · Drug and Alcohol Dependence
  74. Machine Learning–Driven Analysis of Individualized Treatment Effects Comparing Buprenorphine and Naltrexone in Opioid Use Disorder Relapse Prevention
    Majid Afshar, Emma J. Graham Linck, Alexandra B. Spicer, John Rotrosen, Elizabeth Salisbury‐Afshar, Pratik Sinha, Matthew W. Semler, Matthew M. Churpek · 2024 · Journal of Addiction Medicine
  75. Association Between Cost-Sharing and Buprenorphine Prescription Abandonment
    Kao‐Ping Chua, Rena M. Conti, Pooja Lagisetty, Amy S. B. Bohnert, Ushapoorna Nuliyalu, Thuy Dieu Nguyen · 2024 · Journal of General Internal Medicine
  76. Racial Differences in Medications for Opioid Use Disorder Initiation in a Carceral Setting
    Justin Berk, Jessica Brar, Ariel Hoadley, Rosemarie A. Martin · 2024 · Substance Use & Addiction Journal
  77. Naloxone Stigma Among People Who Use Drugs: Characteristics and Associations With Stigma Toward Medication for Opioid Use Disorder
    Devin E. Banks, Xiao Li, Brandon Park, Rachel Winograd, Patricia A. Cavazos‐Rehg · 2024 · Journal of Addiction Medicine
  78. Implementing and documenting cultural adaption of evidence-based practice strategies to reduce opioid overdose deaths: examples and lessons from the HEALing communities study
    Erin Bray Gibson, LaShawn Glasgow, Monica Nouvong, Margaret McGladrey, Darcy A. Freedman, Deborah Chassler, Rachel Vickers‐Smith, Madeline D’Onfro, Dawn Goddard‐Eckrich, Timothy Hunt et al. · 2025 · Discover Public Health
  79. Assessment of the impact of an opioid-specific education series on rates of medication-assisted treatment for opioid use disorder in veterans
    Taylor Kirby, Robert Connell, Travis W Linneman · 2020 · American Journal of Health-System Pharmacy
  80. Treating Opioid Use Disorder in Correctional Settings
    Rachel Simon, Josiah D. Rich, Sarah E. Wakeman · 2021 · Springer eBooks
  81. Exploring the Interactions between Non-Medical Methamphetamine Use and Prescribed Buprenorphine or Naltrexone in Opioid Use Disorder Treatment Retention
    Danielle M. Gainer, Ramzi W. Nahhas, Tyler S. Vanderhoof, Sydney M. Silverstein, Mark D. Wright, Samantha O. Vanderhoof, Shannon C. Miller · 2021 · Substance Use & Misuse
  82. Dealing With the Epidemic of Endocarditis in People Who Inject Drugs
    Dominique Vervoort, Kevin R. An, Malak Elbatarny, Derrick Y. Tam, Adam Quastel, Subodh Verma, Kim Alexander Connelly, Bobby Yanagawa, Stephen Edward Fremes · 2022 · Canadian Journal of Cardiology
  83. Variation in Clinical Characteristics and Longitudinal Outcomes in Individuals with Opioid Use Disorder Diagnosis Codes
    Victoria D. Powell, Colin Macleod, Jeremy B. Sussman, Lewei Allison Lin, Amy S. B. Bohnert, Pooja Lagisetty · 2022 · Journal of General Internal Medicine
  84. Predicting at-risk opioid use three months after ed visit for trauma: Results from the AURORA study
    Brittany E. Punches, Uwe Stolz, Caroline E. Freiermuth, Rachel M. Ancona, Samuel A. McLean, Stacey L. House, Francesca L. Beaudoin, Xinming An, Jennifer Strafford Stevens, Donglin Zeng et al. · 2022 · PLoS ONE
  85. A Patient-Centered Nurse-Supported Primary Care-Based Collaborative Care Program to Treat Opioid Use Disorder and Depression; Design and Protocol for the MI-CARE Randomized Controlled Trial
    Lynn DeBar, Michael A. Bushey, Kurt Kroenke, Jennifer F. Bobb, Michael Schoenbaum, Ella Thompson, Morgan Justice, Douglas Zatzick, Leah Hamilton, Carmit K. McMullen et al. · 2023 · Contemporary Clinical Trials
  86. Sex-related differences in the prevalence of substance use disorders, treatment, and overdose among parents with young children
    Yitong Gao, Elizabeth E. Krans, Qingwen Chen, Scott D. Rothenberger, Kara Zivin, Marian Jarlenski · 2023 · Addictive Behaviors Reports
  87. Integrating Buprenorphine for Opioid Use Disorder into Rural, Primary Care Settings
    Jessica J. B. Wyse, Alison C. Eckhardt, Summer Newell, Adam J. Gordon, Benjamin J. Morasco, Kathleen Ferguson Carlson, Philip Todd Korthuis, Sarah S. Ono, Travis I. Lovejoy · 2024 · Journal of General Internal Medicine
  88. Opting into the Public List of DATA-Waivered Practitioners: Variations by Specialty, Treatment Capacity, and Practitioner Characteristics
    Thuy Dieu Nguyen, Barbara Andraka‐Christou, W. David Bradford, Kosali Ilayperuma Simon · 2021 · Journal of Addiction Medicine
  89. The Lived Experience of Medication for Opioid Use Disorder
    Aimee Techau, Emily L. Gamm, Mia Roberts, Lorraine M. Garcia · 2022 · Journal of Addictions Nursing
  90. Implementing harm reduction kits in an office-based addiction treatment program
    Margaret Shang, Brent Thiel, Jane M. Liebschutz, Kevin L. Kraemer, Ariana Freund, Raagini Jawa · 2023 · Harm Reduction Journal
  91. Impact of implementing primary care-based medication for opioid use disorder on provider and staff perceptions
    Sara Mazzarelli, Audrey L Blewer, Truls Østbye, Katherine Rhodes, Gabriela Plasencia, Lauren Hart, Gregory Sawin · 2024 · Family Practice
  92. An initial randomized controlled trial of a Combined Medication and Behavioral Activation Treatment (CoMBAT) for people with opioid use disorder
    Jaclyn M. W. Hughto, Landon D. Hughes, Kimberly M. Nelson, Nicholas S. Perry, Matthew J. Mimiaga, Katie B. Biello, Amelia Bailey, David W. Pantalone · 2024 · Journal of Substance Use and Addiction Treatment
  93. Identifying and responding to policy-related barriers, facilitators, and misunderstandings in the HEALing communities study: A community-driven approach
    Anita Silwal, Robert M. Bohler, Timothy Hunt, Ramona G. Olvera, Michelle R. Lofwall, Christopher Cook, Katherine R. Marks, Carly L. Bridden, Patricia Rippetoe Freeman, Monica Nouvong et al. · 2025 · International Journal of Drug Policy
  94. Adolescent and Young Adult Access to Opioid Use Disorder Care
    Alexis Ball, Teresa Winstead, Samyukta Singh, Anthony S. Floyd, Caleb J. Banta‐Green · 2025 · PEDIATRICS
  95. Mortality during and following treatment with extended-release naltrexone based on data from two clinical trials
    Linn Gjersing, Lars Tanum, Bente Margrethe Weimand, Kristin Klemmetsby Solli · 2025 · Drug and Alcohol Dependence
  96. Disparities in Treatment and Referral After an Opioid Overdose Among Emergency Department Patients
    Siri Shastry, Joseph Edward Carpenter, Alex J. Krotulski, Jeffrey A. Brent, Paul M. Wax, Kim Aldy, Sharan L. Campleman, Rachel E. Culbreth, Alyssa M. Falise, Adrienne Hughes et al. · 2025 · JAMA Network Open
  97. Patient and Provider Perspectives on the Elimination of Urine Drug Testing in Office-Based Addiction Treatment
    Jacqueline Theisen, Zoe Weinstein, Melissa J. Davoust, Alicia S. Ventura, Kara M. Magane, Anna Cheng, Samantha Blakemore, Juliana Blodgett, Sarah Fielman, Richard Saitz et al. · 2025 · Substance Use & Addiction Journal
  98. Low-Threshold Buprenorphine in Non-Traditional Settings: A Scoping Review
    Anna Patterson, Zachary Davis, Mackenzie Smith, Nihmotallahi Adebayo, Madelyn Perez, Miriam Guzman, Tina Griffin, Dennis P. Watson, Elisabeth A. Poorman, Niranjan S. Karnik et al. · 2025 · Substance Use Research and Treatment
  99. Systematic review of patient‐reported outcome measures for opioid use disorder recovery
    Jarratt D. Pytell, Dennis Pales, Caty Simon, J. Beaudoin, A. Osman, Ellie Svoboda, Paul J. Christine, Daniel D. Matlock, Robert P. Schwartz, Ingrid A. Binswanger · 2025 · Addiction
  100. Improving Outcomes for People With Injection Drug-related Endocarditis: Are Medications for Opioid Use Disorder Enough?
    Simeon D. Kimmel, Carlos del Rı́o · 2019 · Journal of Addiction Medicine